Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Returns For Oncology Investors

This article was originally published in Start Up

Executive Summary

Patently successful and promising immune-oncology technologies, large markets, and attractive returns have factored into impressive investments in companies with cancer-targeting drugs or technologies. A five-plus-year study of fundraising for biopharma, medtech, and diagnostics companies, using deal data from Informa’s Strategic Transactions, indicates strong and steadily building investor confidence in the segment.

You may also be interested in...



Biotech IPOs: High Tide

Since 2013, investors have rallied around biotech IPOs like never before. START-UP looks at the current window and the implications of investor enthusiasm for newly public companies.

Infectious Disease Companies Catch More Investors

Start-Up surveyed investments into, and exits by, private infectious disease-focused companies from 2013 through the first quarter of 2016, using data from Informa’s Pharma Intelligence's Strategic Transactions and Medtrack databases. Our review reveals an increasing amount of money going into these firms, especially those developing novel antibiotics against drug-resistant bacteria or with novel anti-infective drug development platforms.

Investors Boost Metabolic Companies

Investments in endocrine/metabolic disease-focused medtech companies reached a four-year high in 2015. Biopharma companies grabbed the majority of the funds that have been raised since 2012, and among medtechs, those focused on diabetes fared best.

Topics

Related Companies

UsernamePublicRestriction

Register

SC092742

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel